Nanobiotix: 85.7% Overall Response Rate for JNJ-1900 in Lung Cancer
Nanobiotix announced on Sunday the presentation of data from the first part of the phase 2 CONVERGE clinical study, conducted in partnership with Johnson & Johnson. These results focus on the evaluation of the drug candidate JNJ-1900 (NBTXR3), a nanoradioenhancer administered by intra-tumoral injection, in patients with stage 3 inoperable non-small cell lung cancer.
Efficacy Results Observed in the First Evaluated Cohort
The CONVERGE study assessed JNJ-1900 (NBTXR3) in combination with concurrent chemoradiotherapy and consolidation with durvalumab. Initial findings indicate that intra-tumoral or intra-nodal injection of the drug candidate is feasible and can be safely performed in this patient population.
Among the 7 patients who completed the treatment, the overall response rate was 85.7% (6 patients), while the complete response rate was 57.1% (4 patients). The presentation reported, according to preliminary data, disease control in all 7 evaluable patients (7/7). The absence of disease progression and the progressive improvement in response suggest a potential for long-term durability.
Mechanism of Action and Expanded Development Program
JNJ-1900 (NBTXR3) consists of functionalized hafnium oxide nanoparticles. Administered by intra-tumoral injection, the drug candidate is then activated by radiotherapy. Its physical mechanism of action is designed to induce the death of tumor cells in the injected tumor and trigger an adaptive immune response.
Nanobiotix collaborates with world-class partners to expand the development of the drug candidate. The company announced a licensing agreement with Janssen Pharmaceutica NV (Johnson & Johnson) for the co-development and commercialization of JNJ-1900 (NBTXR3). Among its clinical programs, Nanobiotix is developing the phase 3 NANORAY-312 study in head and neck cancers. This program had also received a Fast Track designation from the FDA, according to previous communications from the company.
